Pulmatrix

Pulmatrix

Pulmatrix

Pulmatrix develops inhaled therapies for the treatment, prevention and transmission of infectious and progressive respiratory diseases.
Founded
2003
Raised
$43.7M
Follow us
Alexa global traffic share
Latest funding Show all
Team Size
10+
Employees
$10,000,000 Angel
prnewswire

Pulmatrix Raises $10 Million Private Placement; To Begin Trading on NASDAQ under "PULM"

Xconomy

After Reinvention, Pulmatrix Wraps Up Ruthigen Deal, Heads to Nasdaq

Health Strategy